Abstract: VS-4718, also known as PND-1186, is an orally available, highly selective, and reversible small-molecule inhibitor of focal adhesion kinase (FAK). Emerging research highlights its significant potential in targeting the tumor microenvironment (TME) and overcoming multidrug resistance across various aggressive malignancies, including pancreatic ductal adenocarcinoma (PDAC) and triple-negative breast cancer (TNBC). By inhibiting FAK autophosphorylation, VS-4718 disrupts critical tumor-stroma interactions, reduces extracellular matrix (ECM) production by stellate cells, and impairs cancer cell migration, proliferation, and survival. Furthermore, VS-4718 has demonstrated the ability to radiosensitize tumor cells, enhance the oncolytic activity of virotherapies, and antagonize multidrug resistance by inhibiting the efflux function of ABC transporters. Despite its modest efficacy as a monotherapy in clinical trials, its ability to modulate the fibrotic and immunosuppressive TME positions VS-4718 as a highly promising candidate for rational combination therapies.
1. Introduction
Pancreatic ductal adenocarcinoma (PDAC) and triple-negative breast cancer (TNBC) are among the most aggressive and difficult-to-treat malignancies, largely due to their complex molecular survival mechanisms and the presence of a dense, desmoplastic tumor microenvironment (TME) [1][2]. The TME, characterized by extensive fibrosis and immunosuppression, acts as a physical and biological barrier that promotes tumor progression, metastasis, and resistance to standard therapies such as chemotherapy and radiotherapy [1][3].
Focal adhesion kinase (FAK), a non-receptor tyrosine kinase encoded by the PTK2 gene, is frequently overexpressed in these cancers and is considered a critical driver of the fibrotic TME and cancer stem cell renewal [1][3]. FAK integrates signals from integrins and growth factor receptors to regulate cell migration, survival, and proliferation [4]. VS-4718 (previously known as PND-1186) is a potent, selective FAK tyrosine kinase inhibitor (TKI) that has entered clinical trials (e.g., Phase I trials for acute myeloid leukemia, metastatic cancer, and advanced PDAC) [1][3]. Current research heavily focuses on its ability to remodel the TME, sensitize tumors to radiation and oncolytic viruses, and combat multidrug resistance.
2. Pharmacological Activity
Tumor Microenvironment Modulation and Radiosensitization: In PDAC, VS-4718 exhibits dose-dependent cytotoxicity across multiple cell lines (e.g., Panc-1, PSN-1, Capan-1, Beta-TC-3), with IC50 values ranging from 1.23 μM to over 60 μM depending on the cell line's inherent sensitivity [1][3]. Crucially, VS-4718 acts as a potent radiosensitizer in vitro, but this effect is highly dependent on the TME. Radiosensitization is achieved specifically in the presence of ECM-producing pancreatic stellate cells or a collagen I matrix, highlighting its role in disrupting stroma-derived survival signals [1]. In 3D multicellular tumor spheroid models, the combination of VS-4718 and radiotherapy significantly inhibits tumor aggregate growth compared to radiation alone [1].
Enhancement of Virotherapy: VS-4718 has been investigated in combination with the oncolytic coxsackievirus B3 (CVB3) strain PD-H. In sensitive PDAC cell lines (such as Capan-1, AsPC-1, and Beta-TC-3), co-treatment with VS-4718 and PD-H results in synergistic or additive enhancement of tumor cell lysis at low to medium doses, presenting a novel strategy to improve oncolytic virotherapy outcomes [3].
Inhibition of Tumor Growth and Migration in TNBC: In TNBC models, VS-4718 effectively prevents tumor cell proliferation, colony formation, and spheroid expansion stimulated by insulin-like growth factor-1 (IGF-1) [2]. Additionally, it abolishes the migratory effects and wound closure capabilities of TNBC cells triggered by estrogens (E2 and G1) [4].
Reversal of Multidrug Resistance: Beyond its effects on the TME and cell migration, VS-4718 has been shown to antagonize multidrug resistance in cancer cells overexpressing ABCB1 and ABCG2 by directly inhibiting the efflux function of these ATP-binding cassette (ABC) transporters [2].
3. Molecular Mechanism of Action
VS-4718 functions primarily by reversibly binding to FAK and inhibiting its autophosphorylation at the Tyrosine-397 (Y397) residue, a critical step for full FAK activation and downstream signaling [1][3]. It also exhibits inhibitory activity against the related kinase PYK2 [3]. The downstream mechanistic effects of this inhibition are multifaceted:
Disruption of Stroma-Tumor Crosstalk: VS-4718 directly targets pancreatic stellate cells, reducing their viability and markedly decreasing their production of ECM components like collagen. This intercepts the β1-integrin-FAK signaling axis that normally provides radioprotective and survival signals to cancer cells [1].
DNA Repair Impairment and Cell Cycle Arrest: When combined with radiotherapy, VS-4718 impairs the DNA damage response in cancer cells. This is evidenced by a significant increase in residual γ-H2AX foci 24 hours post-irradiation. Furthermore, FAK inhibition blocks the cell cycle, arresting cells in the highly radiation-sensitive G2/M phase [1].
Inhibition of the IGF-1/IGF-1R/FAK/YAP Axis: In TNBC, IGF-1 stimulates a direct interaction between IGF-1R and FAK. VS-4718 blocks this interaction, preventing downstream AKT phosphorylation. Consequently, it inhibits the nuclear accumulation and transcriptional activity of YAP (a Hippo pathway effector), thereby suppressing the expression of YAP-target genes such as CTGF and Cyr61, which are essential for tumor growth [2].
Suppression of the GPER/FAK/STAT3 Axis: Estrogenic signaling via the G-protein-coupled estrogen receptor (GPER) triggers FAK Y397 phosphorylation. VS-4718 intercepts this pathway, preventing the nuclear accumulation of STAT3 and the subsequent transactivation of target genes (c-FOS, EGR1, and CTGF) required for TNBC cell migration [4].
4. Structure-Activity Relationship (SAR)
While the provided literature does not detail extensive chemical structure-activity relationship (SAR) modifications for VS-4718, it is characterized as a highly selective, reversible small-molecule inhibitor of the FAK kinase domain. Its primary molecular action is the specific blockade of the autophosphorylation of the Tyr-397 site [1][3]. At micromolar concentrations, VS-4718 maintains high selectivity, with negligible off-target activity reported except for PYK2 and FLT3 (the latter being expressed only in cells of hematopoietic origin) [1][3]. The structural basis of its efficacy lies in its ability to outcompete ATP binding, thereby shutting down the scaffolding and kinase functions of FAK that drive TME fibrosis and multidrug resistance.
5. Current Limitations
Despite robust preclinical data, the clinical translation of VS-4718 faces several challenges:
Modest Monotherapy Efficacy: In clinical trials, FAK inhibitors, including VS-4718, have demonstrated only limited efficacy as monotherapies. They typically yield modest clinical activity characterized by low rates of partial responses and disease stabilization in patients with advanced solid malignancies [3].
Variable Cellular Sensitivity: Tumor cell lines exhibit highly variable sensitivity to VS-4718. For instance, while Capan-1 and PSN-1 cells are highly responsive, MIA PaCa-2 cells display significant resistance [1][3]. This fluctuation in IC50 values has been attributed to differences in the expression of regulatory proteins, such as Merlin, which modulates FAK function [1].
Antagonistic Interactions in Virotherapy: Because VS-4718 is highly cytotoxic, it can dose-dependently inhibit the replication machinery of oncolytic viruses (such as PD-H) even at subcytotoxic concentrations. In resistant cell lines or at high doses, this leads to antagonistic interactions, diminishing the overall oncolytic benefit of the combination therapy [3].
6. Future Perspectives
The future clinical utility of VS-4718 lies in rational combination strategies rather than monotherapy. Because FAK inhibition effectively remodels the desmoplastic stroma and impairs DNA repair, combining VS-4718 with radiotherapy, conventional chemotherapy, or immune checkpoint inhibitors holds great promise for overcoming TME-mediated resistance in PDAC and TNBC [1][3].
To maximize the efficacy of FAK inhibitor/oncolytic virus combinations, future research must focus on optimizing treatment regimens. Sequential, rather than simultaneous, administration of VS-4718 and virotherapies may prevent the drug from inhibiting viral replication while still priming the TME for viral spread [3]. Furthermore, the development of predictive biomarkers and the use of patient-derived tumor specimens will be essential to identify responder versus non-responder populations, thereby personalizing therapy and minimizing the risk of treatment failure [3]. Finally, advanced in vivo models are required to fully validate the radiosensitizing and TME-modulating effects of VS-4718 observed in 3D multicellular assays [1].
